Pharmaceutical Raw Materials: How to Distinguish API, Excipients, and Intermediates and Why It Matters for Drug Manufacturing

Photo: Trnava University / Unsplash

Drug production requires the precise selection and combination of various types of pharmaceutical raw materials. The foundation is active pharmaceutical ingredients (APIs), which provide the therapeutic effect, but excipients – auxiliary substances that improve stability, solubility, or taste of the drug – are equally important. The third group consists of intermediates, key synthesis by-products of APIs. Each of these categories has specific requirements for purity, storage, and documentation, which directly affect the final quality of the drug. Understanding their differences and properties is crucial for complying with regulatory standards and optimizing the manufacturing process.

What are pharmaceutical raw materials and why their categorization is key

Pharmaceutical raw materials form the foundation of every medicinal product, and their correct classification is crucial for ensuring the quality, safety, and efficacy of the final product. In industrial drug manufacturing, raw materials are divided into three main categories: active pharmaceutical ingredients (APIs), excipients, and intermediates. Each of these groups plays a distinct role in the manufacturing process, has specific quality requirements, and faces different regulatory demands. While APIs carry the therapeutic effect, excipients ensure stability, solubility, or taste of the drug, and intermediates serve as chemical intermediates in API synthesis. Incorrect classification of a raw material can lead to manufacturing errors, contamination, or even failure of the registration process.

The categorization of raw materials affects not only the technological production process but also the economics of the process. For example, APIs are subject to stricter purity controls (typically 98–99.9%) and require validated analytical methods, whereas excipients may have broader specifications. Intermediates, on the other hand, often require specific storage conditions (e.g., temperatures below 25 °C or protection from moisture), and their quality directly impacts the yield of the final API. Therefore, it is essential for drug manufacturers to have clearly defined specifications for each category of raw materials and suppliers who reliably meet these requirements.

Active Pharmaceutical Ingredients (APIs): The Heart of Every Drug

Active pharmaceutical ingredients (APIs) are chemical compounds or their mixtures that have a direct therapeutic effect on the organism. Their production is subject to the strictest regulatory requirements, including REACH regulations and Good Manufacturing Practice (GMP) guidelines. APIs must meet high purity standards, typically with an active substance content exceeding 98%, and their production must be fully documented from raw materials to the final product. Typical examples of APIs include antibiotics, analgesics, or antihypertensives, which are often produced through multi-step syntheses or biotechnological processes.

A key aspect of working with APIs is ensuring their stability and consistency. Even minor deviations in purity or the presence of impurities can affect the efficacy of a drug or cause undesirable side effects. Manufacturers must therefore carry out regular checks using chromatographic methods (e.g., HPLC) and spectroscopic analyses. Validation of manufacturing processes is also important, as it confirms that each API batch meets predefined parameters. Special requirements apply to the packaging material (e.g., inert containers) and transport conditions for API distribution to prevent degradation or contamination.

Photo: Hans Reniers / Unsplash

Excipients: The Invisible Helpers with a Key Role

Although excipients, also known as auxiliary substances, do not have a therapeutic effect of their own, most medicines could not exist without them. Their role is to improve the physicochemical properties of the drug, facilitate its administration, or ensure stability during storage. The most common excipients include fillers (e.g., lactose, microcrystalline cellulose), binders, solvents, preservatives, or substances modifying taste and odor. The choice of the right excipient depends on the dosage form – tablets require different auxiliary substances than injectable solutions or ointments.

Unlike APIs, excipients do not have to meet such strict purity requirements, but their quality is still crucial. For example, the presence of microbial contamination in an excipient for injectable preparations can cause serious complications. Manufacturers must therefore adhere to pharmaceutical quality standards and perform incoming inspections for each batch. It is also important to consider the compatibility of excipients with APIs – some combinations can lead to chemical reactions that reduce the drug's efficacy. Modern trends in excipients include the development of multifunctional substances that perform several roles simultaneously, thereby reducing the number of components in the drug.

Intermediates: The Bridge Between Raw Material and Final API

Intermediates are chemical by-products formed during the synthesis of active pharmaceutical ingredients. Unlike APIs, they do not yet have a therapeutic effect, but their quality directly influences the properties of the final product. A typical example is API precursors, which undergo further chemical transformations before achieving the desired structure. The production of intermediates often takes place in separate facilities, where reaction conditions (temperature, pressure, catalysts) are optimized to achieve maximum yield and purity.

Working with intermediates requires a specific approach to analysis and storage. Since these are unstable compounds, they often need to be stored under controlled conditions (e.g., in an inert atmosphere or at low temperatures). Analytical methods for monitoring intermediates include chromatography and mass spectrometry, which allow tracking reaction progress and identifying impurities. It is also important to adhere to Good Manufacturing Practice (GMP) principles, even though intermediates are not subject to regulations as strict as those for APIs. Proper handling is crucial for production economics—poor-quality intermediates can lead to low API yields and increased costs.

Photo: ThisisEngineering / Unsplash

Quality Requirements and Regulations: Why Not Every Raw Material Is Suitable for Pharmaceutical Use

Pharmaceutical raw materials are subject to strict quality standards that significantly exceed the requirements for common chemicals. A key document is the pharmacopoeia (e.g., European or American), which defines specifications for APIs, excipients, and some intermediates. These standards include limits on impurity content, microbiological purity, physico-chemical properties (such as solubility, melting point, or particle size distribution), and methods for their verification. For example, APIs often require a purity of over 98%, with residual solvents not exceeding the specified limits according to ICH Q3C guidelines. For excipients, critical parameters include compatibility with APIs, stability during storage, or the absence of pyrogens in substances intended for parenteral administration.

The regulatory framework also includes systems such as REACH (for chemicals in general) and GMP (Good Manufacturing Practice) for the production and control of pharmaceutical raw materials. Manufacturers must demonstrate compliance with these regulations through validated manufacturing processes, regular audits, and documentation for each batch. For intermediates, which are not directly part of the final drug, the requirements are less stringent but must still meet basic purity and safety criteria. An important aspect is traceability – each raw material must be traceable back to the original manufacturer, which is crucial for addressing potential quality deviations or drug recalls.

Technological Challenges in Processing Different Types of Raw Materials

Processing pharmaceutical raw materials requires specific technological approaches that vary depending on their category. APIs often require precise handling due to their reactivity or sensitivity to moisture, light, or temperature. For example, some cytostatics or hormones are processed in an inert nitrogen atmosphere and under controlled temperatures to prevent degradation. For excipients, homogeneity is key – for instance, in fillers for tablets, the particle size distribution must be as uniform as possible to ensure consistent weight and solubility of the final product. Technologies such as fluid bed granulation or wet granulation are used to improve the flow properties of powders and reduce dustiness.

Intermediates present a specific challenge because their properties can differ significantly from the final API. During synthesis, toxic or corrosive intermediates are often handled, requiring special reactor materials (e.g., glass or high-resistance stainless steel) and effective waste gas purification systems. Another critical point is isolation and drying – some intermediates are hygroscopic or thermolabile, necessitating the use of lyophilization or vacuum drying. For all categories of raw materials, manufacturing processes must be validated and reproducible to minimize the risk of contamination or variability between batches.

Economic and Logistical Aspects: How Raw Material Selection Impacts Drug Costs and Availability

The choice of pharmaceutical raw materials has a direct impact on drug production economics. APIs typically represent the most significant cost factor—their price can account for up to 70% of the total production costs of a generic drug. Manufacturers therefore seek ways to optimize API synthesis, for example, through catalytic processes or continuous production, which reduces energy and raw material consumption. While excipients do not incur such high costs, their quality and availability can affect production capacity. For instance, a shortage of microcrystalline cellulose or lactose can lead to disruptions in tablet production.

The logistics of pharmaceutical raw materials require special attention due to their sensitivity and regulatory requirements. APIs and some excipients are often stored and transported under controlled conditions (temperature, humidity, light protection), increasing logistics costs. For intermediates, supply chain synchronization is key—delays in the delivery of a single intermediate can halt the entire API synthesis. Manufacturers therefore prefer suppliers with GMP certification and robust quality management systems. An important trend is the localization of production—for example, shifting from Asian API suppliers to European manufacturers can reduce risks associated with long lead times and customs complications, though often at higher costs.

Do you need raw materials with certified quality?

GCG Group supplies pharmaceutical raw materials with complete documentation, including safety data sheets (SDS) and technical specifications. Our experts will help you select suitable substances for your production and advise on legislative requirements. Contact us – or browse our catalog of over 1,300 products right away.